5





ABSTRACT OF THE DISCLOSURE

Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life *in vivo*. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.